Public reporting of black participation in anti-hypertensive drug clinical trials
Authors' conclusion
Despite Black Americans carrying the highest burden of disease for essential hypertension, they are underrepresented in anti-hypertension clinical trials and their overall participation has decreased between 2010 and 2020. In addition, there is major underreporting of trial participant race.
Study context
- Population
- Antihypertensive drug trials on ClinicalTrials.gov reporting results 2010–2020trials
- Participants
- 97 trials
- Exposure
- Industry vs non-industry sponsored trials
- Outcome
- Representation of Black participants by trial sponsorship type
Methodological detailsClinicalTrials.gov registry analysis
- ClinicalTrials.gov registry analysis
Main finding
As reported in the abstract
Percent of Black patients enrolled
- Minimal differences in percent of Black patients enrolled by sponsorship type
Observational data: associations, not effects.
Further findings
Non-reporting of participant race
Time from study completion to results reporting on ClinicalTrials.gov
Original publication
Public reporting of black participation in anti-hypertensive drug clinical trials. Am Heart J. Published 11 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →